Literature DB >> 27500424

Glycoproteomic Analysis of Malignant Ovarian Cancer Ascites Fluid Identifies Unusual Glycopeptides.

Suzanne Miyamoto1, L Renee Ruhaak2, Carol Stroble1, Michelle R Salemi3, Brett Phinney3, Carlito B Lebrilla2, Gary S Leiserowitz4.   

Abstract

Ovarian cancer is a major cause of cancer mortality among women, largely due to late diagnosis of advanced metastatic disease. More extensive molecular analysis of metastatic ovarian cancer is needed to identify post-translational modifications of proteins, especially glycosylation that is particularly associated with metastatic disease to better understand the metastatic process and identify potential therapeutic targets. Glycoproteins in ascites fluid were enriched by affinity binding to lectins (ConA or WGA) and other affinity matrices. Separate glycomic, proteomic, and glycopeptide analyses were performed. Relative abundances of different N-glycan groups and proteins were identified from ascites fluids and a serum control. Levels of biomarkers CA125, MUC1, and fibronectin were also monitored in OC ascites samples by Western blot analysis. N-Glycan analysis of ascites fluids showed the presence of large, highly fucosylated and sialylated complex and hybrid glycans, some of which were not observed in normal serum. OC ascites glycoproteins, haptoglobin, fibronectin, lumican, fibulin, hemopexin, ceruloplasmin, alpha-1-antitrypsin, and alpha-1-antichymotrypsin were more abundant in OC ascites or not present in serum control samples. Further glycopeptide analysis of OC ascites identified N- and O-glycans in clusterin, hemopexin, and fibulin glycopeptides, some of which are unusual and may be important in OC metastasis.

Entities:  

Keywords:  N-glycans; glycopeptides; glycoproteomics; malignant ascites; mass spectrometry; ovarian cancer; proteomics

Mesh:

Substances:

Year:  2016        PMID: 27500424      PMCID: PMC5466807          DOI: 10.1021/acs.jproteome.6b00548

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  70 in total

1.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search.

Authors:  Andrew Keller; Alexey I Nesvizhskii; Eugene Kolker; Ruedi Aebersold
Journal:  Anal Chem       Date:  2002-10-15       Impact factor: 6.986

2.  Secreted 70kDa lumican stimulates growth and inhibits invasion of human pancreatic cancer.

Authors:  Tetsushi Yamamoto; Yoko Matsuda; Kiyoko Kawahara; Toshiyuki Ishiwata; Zenya Naito
Journal:  Cancer Lett       Date:  2012-01-20       Impact factor: 8.679

3.  Nano-LC-MS/MS of glycopeptides produced by nonspecific proteolysis enables rapid and extensive site-specific glycosylation determination.

Authors:  John W Froehlich; Mariana Barboza; Caroline Chu; Larry A Lerno; Brian H Clowers; Angela M Zivkovic; J Bruce German; Carlito B Lebrilla
Journal:  Anal Chem       Date:  2011-06-28       Impact factor: 6.986

4.  Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.

Authors:  Raluca A Budiu; Gina Mantia-Smaldone; Esther Elishaev; Tianjiao Chu; Julia Thaller; Kathryn McCabe; Diana Lenzner; Robert P Edwards; Anda M Vlad
Journal:  Cancer Immunol Immunother       Date:  2011-04-02       Impact factor: 6.968

Review 5.  Regulation of the metastatic cell phenotype by sialylated glycans.

Authors:  Matthew J Schultz; Amanda F Swindall; Susan L Bellis
Journal:  Cancer Metastasis Rev       Date:  2012-12       Impact factor: 9.264

6.  Bitter sweetness of complexity.

Authors:  A K Horst; C Wagener
Journal:  Top Curr Chem       Date:  2009

7.  Enhanced expression of lumican inhibited the attachment and growth of human embryonic kidney 293 cells.

Authors:  Toshiyuki Ishiwata; Tetsushi Yamamoto; Kiyoko Kawahara; Yoko Kawamoto; Yoko Matsuda; Shunji Ishiwata; Zenya Naito
Journal:  Exp Mol Pathol       Date:  2010-02-04       Impact factor: 3.362

8.  Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer.

Authors:  Karen L Abbott; Alison V Nairn; Erica M Hall; Marc B Horton; John F McDonald; Kelley W Moremen; Daniela M Dinulescu; Michael Pierce
Journal:  Proteomics       Date:  2008-08       Impact factor: 3.984

9.  Employment of tandem mass spectrometry for the accurate and specific identification of oligosaccharide structures.

Authors:  Shuai Wu; Juli Salcedo; Ning Tang; Keith Waddell; Rudolf Grimm; J Bruce German; Carlito B Lebrilla
Journal:  Anal Chem       Date:  2012-08-21       Impact factor: 6.986

10.  Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins.

Authors:  Bensheng Li; Hyun Joo An; Crystal Kirmiz; Carlito B Lebrilla; Kit S Lam; Suzanne Miyamoto
Journal:  J Proteome Res       Date:  2008-07-22       Impact factor: 4.466

View more
  16 in total

1.  Multiple Reaction Monitoring for the Quantitation of Serum Protein Glycosylation Profiles: Application to Ovarian Cancer.

Authors:  Suzanne Miyamoto; Carol D Stroble; Sandra Taylor; Qiuting Hong; Carlito B Lebrilla; Gary S Leiserowitz; Kyoungmi Kim; L Renee Ruhaak
Journal:  J Proteome Res       Date:  2017-12-19       Impact factor: 4.466

2.  Immunoglobulin A N-glycosylation Presents Important Body Fluid-specific Variations in Lactating Mothers.

Authors:  Elisha Goonatilleke; Jennifer T Smilowitz; Karina V Mariño; Bruce J German; Carlito B Lebrilla; Mariana Barboza
Journal:  Mol Cell Proteomics       Date:  2019-08-13       Impact factor: 5.911

Review 3.  Recent Advances in the Mass Spectrometry Methods for Glycomics and Cancer.

Authors:  Muchena J Kailemia; Gege Xu; Maurice Wong; Qiongyu Li; Elisha Goonatilleke; Frank Leon; Carlito B Lebrilla
Journal:  Anal Chem       Date:  2017-10-31       Impact factor: 6.986

Review 4.  Methods for quantification of glycopeptides by liquid separation and mass spectrometry.

Authors:  Haidi Yin; Jianhui Zhu
Journal:  Mass Spectrom Rev       Date:  2022-01-31       Impact factor: 9.011

Review 5.  Sialic acids in gynecological cancer development and progression: Impact on diagnosis and treatment.

Authors:  Anna Y Berghuis; Johan F A Pijnenborg; Thomas J Boltje; Johanna M A Pijnenborg
Journal:  Int J Cancer       Date:  2021-11-17       Impact factor: 7.316

Review 6.  Alpha-1-antichymotrypsin as a novel biomarker for diagnosis, prognosis, and therapy prediction in human diseases.

Authors:  Yanxia Jin; Weidong Wang; Qiyun Wang; Yueyang Zhang; Kashif Rafiq Zahid; Umar Raza; Yongsheng Gong
Journal:  Cancer Cell Int       Date:  2022-04-19       Impact factor: 6.429

7.  Lumican delays melanoma growth in mice and drives tumor molecular assembly as well as response to matrix-targeted TAX2 therapeutic peptide.

Authors:  Albin Jeanne; Valérie Untereiner; Corinne Perreau; Isabelle Proult; Cyril Gobinet; Camille Boulagnon-Rombi; Christine Terryn; Laurent Martiny; Stéphane Brézillon; Stéphane Dedieu
Journal:  Sci Rep       Date:  2017-08-09       Impact factor: 4.379

8.  Understanding Ovarian Cancer: iTRAQ-Based Proteomics for Biomarker Discovery.

Authors:  Agata Swiatly; Agnieszka Horala; Jan Matysiak; Joanna Hajduk; Ewa Nowak-Markwitz; Zenon J Kokot
Journal:  Int J Mol Sci       Date:  2018-07-31       Impact factor: 5.923

9.  Breast cancer diagnosis by analysis of serum N-glycans using MALDI-TOF mass spectroscopy.

Authors:  Sae Byul Lee; Shambhunath Bose; Sei Hyun Ahn; Byung Ho Son; Beom Seok Ko; Hee Jeong Kim; Il Yong Chung; Jisun Kim; Woochang Lee; Myung-Su Ko; Kyungsoo Lee; Suhwan Chang; Hyoung Soon Park; Jong Won Lee; Dong-Chan Kim
Journal:  PLoS One       Date:  2020-04-09       Impact factor: 3.240

10.  Lectins: an effective tool for screening of potential cancer biomarkers.

Authors:  Onn Haji Hashim; Jaime Jacqueline Jayapalan; Cheng-Siang Lee
Journal:  PeerJ       Date:  2017-09-07       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.